Skip to content
Open in App
Daiichi Sankyo logo

Daiichi Sankyo

web2

Daiichi Sankyo Company, Limited manufactures and sells pharmaceutical products in Japan and int...

Symbol · 4568
Company profile

About

Daiichi Sankyo Company, Limited manufactures and sells pharmaceutical products in Japan and internationally. The company offers Enhertu for the treatment of HER2 positive and low breast cancer, HER2 positive gastric or gastroesophageal junction adenocarcinoma, and HER2 positive solid tumors; Turalio, an oral small molecule for colony stimulating factor 1 receptor, KIT proto-oncogene receptor tyrosine kinase, and FMS-like tyrosine kinase 3, as well as symptomatic TGCT; Vanflyta, a FLT3 inhibitor for the treatment of acute myeloid leukemia; Injectafer, a ferric carboxymaltose injection for the treatment of iron deficiency; and Datroway for the treatment of HR positive and HER2 negative breast cancer, as well as NSCLC. It also provides Lixiana and Savaysa, which are direct factor Xa inhibitors; Minnebro, Olmetec, Olmetec Plus, Rezaltas, Sevikar, and Sevikar HCT, which are antihypertensive agents; Nilemdo that lowers cholesterol; Nustendi, a fixed-dose combination tablet of bempedoic acid and ezetimibe that reduces cholesterol; and Efient, an anti-platelet agent. In addition, the company offers Canalia for the treatment of type 2 diabetes mellitus; Emgality for the treatment of migraine attacks; Pralia for the treatment of osteoporosis and bone erosion associated with rheumatoid arthritis; Ranmark for the treatment of bone complications and GCTB; Tarlige for the treatment of neuropathic pain; Venofer for the treatment of iron deficiency anemia; Vimpat, an anti-seizure medication; and Reyvow for the treatment of acute migraine attacks. Further, it provides Daichirona, a coronavirus RNA vaccine; Flumist, an intranasal live attenuated influenza vaccine; adsorbed cell culture-derived influenza vaccine; measles rubella combined vaccine; and mump vaccine. The company was formerly known as Sankyo Co. Ltd. and changed its name to Daiichi Sankyo Company, Limited in September 2005. Daiichi Sankyo Company, Limited was founded in 1899 and is headquartered in Chuo, Japan.

Explore by sector

Explore this sector

Market identity

Exchange listings

Listing identities only. Orbitrum does not publish live prices or market performance on this public profile.

Progress

Roadmap

Enhertu granted U.S. Priority Review in HER2 positive early breast cancer

KEY STEP

The FDA accepted the supplemental Biologics License Application for Enhertu and granted Priority Review for adults with HER2 positive breast cancer who have residual invasive disease after neoadjuvant HER2 targeted treatment. The application is based on DESTINY Breast05 phase 3 results.

Roadmap reference

Enhertu approved in US for neoadjuvant HER2 positive early breast cancer

KEY STEP

The FDA approved Enhertu followed by a taxane, trastuzumab and pertuzumab for neoadjuvant treatment of adults with HER2 positive stage II or stage III breast cancer. The approval is based on DESTINY Breast11 and expands Enhertu into treatment before surgery in early breast cancer.

Roadmap reference
People

Company team

TN

Takaaki Nishii

Independent Outside Chairperson

Company leadership profile.

HO

Hiroyuki Okuzawa

President, CEO & Representative Director

Company leadership profile.

TM

Takashi Matsumoto

Sr. Exec Ofcr, Chief Corp Affairs Ofcr, Head of Global Corp Affairs & HR, CHRO & Director

Company leadership profile.

JK

Joseph Kenneth Keller

Head of Oncology Business Unit & Global Oncology Business and Director

Company leadership profile.

SM

Stuart Mackey

Global Head of Business Development & Director

Company leadership profile.

SU

Shizuko Ueno

Senior Executive Officer, Head of Japan Business Unit & Director

Company leadership profile.

MA

Miyuki Arai

Chairperson Member of Audit & Supervisory Board

Company leadership profile.

YH

Yo Honma

Independent Outside Director

Company leadership profile.

AH

Akihiro Hiroshi Watanabe

Independent Outside Director

Company leadership profile.

YK

Yasuhiro Komatsu

Independent Outside Director

Company leadership profile.

RK

Reiko Kinoshita

Independent Outside Director

Company leadership profile.

MW

Masako Watanabe

Outside Audit & Supervisory Board Member

Company leadership profile.

TY

Terumichi Yokoyama

Audit & Supervisory Board Member

Company leadership profile.

TM

Takashi Murata

Outside Audit & Supervisory Board Member

Company leadership profile.

ST

Sayuri Tago

Outside Audit & Supervisory Board Member

Company leadership profile.

Expert coverage

1 expert evaluated Daiichi Sankyo.

Orbitrum research

Experts evaluating Daiichi Sankyo

Explore the public profiles of experts who have evaluated this project.

Orbitrum Academy

Learn how to read a project assessment